1. Usulan rekomendasi
Esomeprazol belum dapat diusulkan untuk direkomendasikan untuk esofagitis refluks erosif pada harga saat ini.
Alasan usulan
- Dibandingkan dengan omeprazol 20 mg sekali sehari, esomeprazol memberi tambahan 0,03 tahun hidup berkualitas (QALY) per pasien dengan tambahan biaya Rp 8,6 juta per pasien.
- Rasio Rp 301,1 juta per QALY melampaui acuan tiga kali PDB per kapita (Rp 225 juta per QALY).
- Rasio tersebut baru mencapai acuan satu kali PDB per kapita pada biaya obat Rp 554.873 atau lebih rendah.
2. Informasi tentang esomeprazol
| Nama generik | Esomeprazol (esomeprazole) |
|---|---|
| Kode ATC | A02BC05 |
| Bidang terapi | Saluran cerna dan metabolisme |
| Program penilaian | Penilaian obat baru |
| Intervensi yang dinilai | Esomeprazol 40 mg sekali sehari |
| Pembanding | omeprazol 20 mg sekali sehari |
| Formularium Nasional | Tercantum (FKRTL) |
| Izin edar BPOM | Ya |
| Katalog elektronik pengadaan | Ya |
| Daftar Obat Esensial WHO | Tidak |
| Penyakit terkait dalam kompetensi layanan primer | Gastritis (K29) |
| Perluasan akses FKTP | Reasesmen 1: Hanya dijamin di FKRTL, padahal digunakan untuk salah satu dari 144 penyakit yang wajib dituntaskan dokter di FKTP. Dokter layanan primer wajib menangani penyakitnya tetapi tidak dapat meresepkan obatnya. |
| Biaya obat dalam model (per tahun atau per rangkaian terapi) | Rp 1 juta |
3. Pembahasan bukti
| Ukuran | Nilai |
|---|---|
| Tambahan tahun hidup berkualitas per pasien | 0,029 QALY |
| Tambahan biaya per pasien | Rp 8,6 juta |
| Rasio biaya terhadap manfaat | Rp 301,1 juta per QALY |
| Peluang hemat biaya pada Rp 75 juta per QALY | 1,8% |
Hasil lengkap, termasuk simulasi probabilistik dan analisis sensitivitas, tersedia pada halaman bukti.
Keterbatasan
Uraian berikut tersedia dalam bahasa Inggris.
- ADJUDICATED CONSENSUS of two independent builders. Builder A used a 5-year horizon, age 45, healing-only effect (multiplier 1.12) and eso ~Rp 1.31m/yr; builder B used a 10-year horizon, age 50, a richer maintenance/remission state structure with multi-edge benefit (healing 1.10, relapse 0.85, complication 0.90, remission 1.05) and eso ~Rp 4.38m/yr (branded). The final model adopts builder B's 10-year horizon, age 50 and 6-state maintenance structure; builder A's conservative effect framing and generic-esomeprazole price; and builder A's narrower (erosive-confirmed) eligible population.
- This is deliberately framed as a likely-low-value single-enantiomer switch. The modelled healing advantage (multiplier 1.10) plus a small relapse credit (0.90) is anchored to the meta-analytic central estimate (Edwards 2006 ARR ~4%) rather than the single most favourable pivotal trial (Kahrilas/Castell ~8-9.5%); builder B's larger relapse/complication/remission credits were attenuated because PPI maintenance differences are not robustly molecule-specific and the equal-dose 20-vs-20mg difference is only ~2-3%.
- Drug acquisition costs are Indonesian retail/pharmacy-platform proxies (esomeprazole ~Rp 1.31m/yr generic vs omeprazole ~Rp 0.25m/yr) and must be replaced with INAPROC/e-katalog LKPP, BPJS claim, or hospital tender prices; the result is highly sensitive to this price gap (a branded-Nexium scenario and a generic price-parity scenario are both included).
- Indonesia-specific GERD/erosive-oesophagitis transition probabilities, utilities, and complication (stricture/Barrett's) incidence are unavailable; values are anchored to international trial and natural-history literature with the Indonesia EQ-5D-5L general-population value set (Purba 2017) for utility anchoring.
- Long-term PPI class adverse events (fracture, B12, magnesium, CKD, C. difficile, acid rebound) are modelled explicitly but set equal between arms, so they contribute zero net incremental effect in the base case, consistent with the evidence that these are class effects; the small class disutility/cost is applied identically to both arms via utility_adjustments and annual_care_cost_offsets and cancels incrementally.
- Maintenance strategy (continuous vs on-demand vs step-down), adherence, and deprescribing are not explicitly modelled beyond the off_therapy_remission state and would materially affect lifetime cost and PPI-overuse harm.
4. Implementasi
Dengan perkiraan 1.700.000 pasien yang memenuhi syarat, dampak anggaran kumulatif lima tahun diperkirakan tambahan belanja Rp 1,9 triliun. Rincian per tahun tersedia pada halaman implementasi.
Penilaian kapasitas layanan, kesiapan implementasi, dan kesetaraan belum tersedia untuk topik ini.
5. Tim penilai dan status telaah
| Status telaah | Draf, menunggu telaah ahli ekonomi kesehatan |
|---|---|
| Penyusun analisis | ARC Institute |
| Pengesahan komite | Belum ada |